Valganciclovir for cytomegalovirus prophylaxis in liver transplant recipients
نویسندگان
چکیده
منابع مشابه
LETTER TO THE EDITORS Valganciclovir for Cytomegalovirus Prophylaxis in Liver Transplant Recipients
We thank Jain et al. for their interest and correspondence regarding our recently published study. The authors note that the incidence of cytomegalovirus (CMV) disease in our retrospective study was much lower than that reported by others. As acknowledged in our article, we did not use routine surveillance to detect CMV viremia and the true rate of CMV infection could have been higher than what...
متن کاملValganciclovir prophylaxis against cytomegalovirus impairs lymphocyte proliferation and activation in renal transplant recipients.
BACKGROUND Antiviral prophylaxis against cytomegalovirus has been associated with reduced risk of allograft rejection and improved allograft survival after renal transplantation. This phenomenon might not be fully explained by preventing the indirect effects of cytomegalovirus. The effect of antiviral agents on lymphocyte function in patients treated with modern immunosuppression has not been s...
متن کاملThe efficacy and safety of 200 days valganciclovir cytomegalovirus prophylaxis in high-risk kidney transplant recipients.
Late-onset cytomegalovirus (CMV) disease is a significant problem with a standard 3-month prophylaxis regimen. This multicentre, double-blind, randomized controlled trial compared the efficacy and safety of 200 days' versus 100 days' valganciclovir prophylaxis (900 mg once daily) in 326 high-risk (D+/R-) kidney allograft recipients. Significantly fewer patients in the 200-day group versus the 1...
متن کاملOral Valganciclovir as a Preemptive Treatment for Cytomegalovirus (CMV) Infection in CMV-Seropositive Liver Transplant Recipients
OBJECTIVES Cytomegalovirus (CMV) infections in liver transplant recipients are common and result in significant morbidity and mortality. Intravenous ganciclovir or oral valganciclovir are the standard treatment for CMV infection. The present study investigates the efficacy of oral valganciclovir in CMV infection as a preemptive treatment after liver transplantation. METHODS Between 2012 and 2...
متن کاملEfficacy and safety of a lower-dose valganciclovir (valcyte) regimen for cytomegalovirus prophylaxis in kidney and pancreas transplant recipients.
PURPOSE We evaluated the efficacy and safety of the current cytomegalovirus (CMV) prophylaxis regimen used at Virginia Mason Medical Center in Seattle. METHODS A single-center, retrospective analysis was conducted in a regional renal transplantation center at a tertiary teaching facility. STUDY POPULATION Seventy patients who underwent kidney and/or pancreas transplantation from October 200...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Liver Transplantation
سال: 2006
ISSN: 1527-6465,1527-6473
DOI: 10.1002/lt.20782